Poxel Announces its Participation at Upcoming Investor and Scientific Conferences in January 2022

POXEL SA (Euronext – POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced its participation at upcoming investor and scientific conferences in January 2022.

• NASH Tag (hybrid event)

Date: January 6-8, 2022
Park City, Utah, USA
David Moller, Executive Vice President, Chief Scientific Officer (CSO), will present a poster entitled: “Preclinical and Early Clinical Characterization of PXL065 - Deuterium-Stabilized (R)-Pioglitazone – a Potential Novel Oral Therapy for NASH”

• Oddo BHF Forum (virtual)

Date: January 6-11, 2022
Thomas Kuhn, Chief Executive Officer (CEO), and Anne Renevot, Chief Financial Officer, will be available for one-on-one virtual meetings.

• H.C. Wainwright BioConnect (virtual)

Date: January 10-13, 2022
Thomas Kuhn, CEO, will present, and Poxel management team members will be available for one-on-one virtual meetings.

• Degroof Petercam’s Healthcare Conference 2022 (virtual)

Date: January 25, 2022
Thomas Kuhn, CEO, will present, and Poxel management team members will be available for one-on-one virtual meetings.

About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG^® (Imeglimin), Poxel’s first-in-class lead product that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211213006044/en/